胰腺癌靶向药物研究进展

Research Progress of Targeted Drugs for Cancer of Pancreas

胰腺癌是一种恶性程度高、诊断和治疗都困难的消化道恶性肿瘤,其发病率和死亡率近年来都呈上升趋势。在美国,胰腺癌5年生存率小于5%,是预后最差的恶性肿瘤之一。由于胰腺癌对放疗和化疗具有高抗药性,所以目前对胰腺癌的治疗仍然是一个较大的挑战,然而随着靶向药物的进步给胰腺癌的治疗带来了希望。利用分子生物学上的一些治疗方法,比如RNA阻断剂、自杀基因、溶瘤病毒、小分子阻断剂和抗体,取得了瞩目的临床前试验效果。

Cancer of pancreas is a malignant tumor of the digestive tract with high malignancy and difficulty in diagnosis and treatment. Its morbidity and mortality have increased in recent years. The 5-year survival rate in the United States is less than 5%, which is the one of the malignant tumors with worst prognosis. Current treatment of the cancer remains a major challenge because of the high resistance to chemotherapy and radiotherapy. However, advances in targeted drugs have brought hope to the treatment of the cancer. Some treatment methods of molecular biology, such as RNA blockers, suicide genes, oncolytic viruses, small molecule inhibitors and antibodies have achieved remarkable results in preclinical studies.